Literature DB >> 2307543

Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression.

J Fantini1, X J Guo, J Marvaldi, G Rougon.   

Abstract

Suramin, a drug used in the treatment of trypanosomiasis and onchocerciasis inhibits growth-factor-induced mitogenesis. We have investigated the effect of suramin on the growth rate and the morphology of C6 glioma cells cultured in the presence of serum or in a serum-free defined medium. Exponentially growing cells were seeded in multi-dish plates (5 x 10(4) cells/2 cm2 well) in DMEM supplemented with 5% fetal calf serum and were continuously exposed to 1 microgram/ml to 1,000 micrograms/ml suramin. Growth rate (determined 9 days after seeding) was reduced by 5%, 33%, 56% and 97%, respectively for suramin concentrations of 1, 10, 100 and 1000 micrograms/ml. Similar results were obtained in serum-free defined medium (DMEM/F12, 1:1, v:v, EGF 5 ng/ml, transferrin 5 micrograms/ml, selenium 10 ng/ml). Moreover, the concentration of suramin in the culture medium remained constant, demonstrating that the drug was not actively metabolized by the cells. Suramin also induced marked changes in cell morphology: the usual bipolar shape of C6 cells evolved toward a more differentiated appearance, with numerous cellular processes allowing a wide number of cell-cell contacts. In parallel, we monitored expression of an adhesion molecule (N-CAM) at both the mRNA and protein levels. Indirect immunofluoresence technique showed an important increase in cell surface N-CAM expression, starting from a dose of 10 micrograms/ml suramin, whereas total cellular content of N-CAM protein as well as its mRNA levels were unaffected. We also observed that the levels of expression of actin and N-CAM mRNAs decreased by a factor of two in cells maintained in defined medium. However, the relative ratio of N-CAM mRNA over actin mRNA was virtually unchanged following suramin treatment. Taken together, our results suggest that suramin (i) exerts a blocking effect of autocrine growth factors, (ii) interferes with the turn-over mechanisms of N-CAM expressed at the cell surface, either by impairing its endocytosis and/or the process of release of the N-CAM 120 isoform.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307543     DOI: 10.1002/ijc.2910450330

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Carboxymethyl benzylamide dextrans inhibit breast cell growth.

Authors:  R Bagheri-Yarmand; P Bittoun; J Champion; D Letourneur; J Jozefonvicz; S Fermandjian; M Crépin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-12       Impact factor: 2.416

Review 2.  Suramin: an anticancer drug with unique biological effects.

Authors:  A K Larsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  The scientific bases of cancer management: at the interface between fundamental research and clinical practice.

Authors:  M Tubiana
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Cell-type-specific expression of neural cell adhesion molecule (N-CAM) in Ito cells of rat liver. Up-regulation during in vitro activation and in hepatic tissue repair.

Authors:  T Knittel; S Aurisch; K Neubauer; S Eichhorst; G Ramadori
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

5.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 6.  Clinical trials with anticoagulant and antiplatelet therapies.

Authors:  L R Zacharski; K R Meehan; S M Algarra; F A Calvo
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

7.  Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.

Authors:  G Powis; M J Seewald; D Melder; M Hoke; C Gratas; T A Christensen; D E Chapman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Modulation of CD4 by suramin.

Authors:  P D Allen; D H Johnston; M G Macey; N S Williams; A C Newland
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

9.  The inhibitory effect caused by suramin on the paracrine growth of human cancer cells and fibroblasts.

Authors:  H Mukaida; N Hirabayashi; T Hirai; Y Yamashita; T Iwata; S Saeki; T Toge
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.